Full-Time

Regulatory Head of Intercontinental and Gilead Patient Solutions Affiliates and Distributors

Posted on 7/3/2025

Gilead Sciences

Gilead Sciences

10,001+ employees

Develops and commercializes biopharmaceuticals for various diseases

No salary listed

Senior, Expert

Uxbridge, UK + 1 more

More locations: Cambridge, UK

In Person

Category
Risk & Compliance
Legal & Compliance
Required Skills
Business Strategy
Requirements
  • Bachelor's degree in a relevant field; advanced degree (e.g., MBA, PhD) preferred.
  • Proven leadership experience and skills, with the ability to inspire and mentor a diverse and global team.
  • Proven experience in the pharmaceutical/biotechnology industry in regional roles and working with affiliates.
  • Extensive knowledge of regulatory requirements, including ICH requirements and regional requirements and understand current global and regional trends in regulatory affairs and ability to assess the impact of these requirements to the business.
  • A strong track record in developing and implementing regulatory and business strategies and managing complex negotiations with regulatory authorities.
  • Experience in taking a leadership role in updating and preparing the Company for major changes in legislation which impact many departments.
  • Experience in critically reviewing complex technical documents and influencing colleagues across functions.
  • Excellent leadership, planning and organisational skills.
  • Excellent verbal & written English, negotiation, influence, and interpersonal communication skills.
Responsibilities
  • Provide leadership of the Regulatory teams across the region including setting strategic vision and direction.
  • Provide effective management oversight including but not limited to performance management, outsourcing, and operational excellence initiatives.
  • Develop and manage budgets effectively to achieve commercial strategic and operational objectives.
  • Recruit, retain, develop, motivate, and coach talent, fostering professional growth to ensure the organization evolves to be a leading team in industry and ensuring a strong succession pipeline.
  • Contribute to a culture of collaboration, excellence and innovation which inspires team members to be trailblazers and perform at their highest abilities optimizing their effectiveness to enable timely, high quality local submissions through to approvals.
  • Represent the Affiliate and Distributor needs at the GRAD Leadership Team and at the ICR Leadership Team led by Commercial and other teams as needed.
  • Develop and maintain an operating and resourcing model to deliver on business objectives.
  • Assess and develop strategies to mitigate regulatory challenges associated with product development and commercialised products across the ICR and GPS regions.
  • Oversee all regulatory activities in ICR and GPS markets including development and maintenance of procedures, all types of submissions, Advertising and Promotion activities, Early Access Programs and GxP compliance.
  • Ensures policies, procedures and training in place to ensure effective operation and compliance of our distributor partners in IC/GPS.
  • Forms strong, collaborative partnerships with key stakeholders across Regulatory Affairs, CMC Regulatory, Safety, Quality and other functions including General Managers (GMs) and above country GMs across the regions and regional ICR and GPS x-functional partners and leadership, to advance near-term regulatory goals and broader enterprise level objectives.
  • Ensure all processes and submissions adhere to local and international regulatory guidelines, laws, and standards.
  • Stays current with regulatory trends, changes, and requirements related to international regulatory affairs and contributes to international policy development.
  • Act as a deputy for the Vice President GRAD, as required.
Desired Qualifications
  • advanced degree (e.g., MBA, PhD) preferred

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers, hospitals, and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and manufacturing practices. The company's goal is to enhance health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Kymera could lead to breakthroughs in cancer treatment.
  • $11 billion investment in U.S. manufacturing and R&D strengthens market position.
  • Collaboration with AONN+ highlights commitment to improving patient outcomes in oncology.

What critics are saying

  • $202 million settlement may damage reputation and increase regulatory scrutiny.
  • Layoffs of 150 employees could disrupt operations and affect company morale.
  • Significant U.S. investment may strain financial resources and impact short-term profitability.

What makes Gilead Sciences unique

  • Gilead focuses on innovative medicines for unmet medical needs like HIV/AIDS and cancer.
  • The company invests heavily in R&D to maintain a robust pipeline of new treatments.
  • Gilead's strategic partnerships enhance its product offerings and market reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

Pipeline Review
Jun 26th, 2025
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Gilead Sciences and Kymera Therapeutics enter into exclusive option and license agreement to develop novel oral molecular glue CDK2 degraders.

24-7 Press Release
Jun 26th, 2025
Gilead Sciences, Inc. proudly Supports Unite for HER's Metastatic Breast Cancer Sustainer Program

PHILADELPHIA, PA, June 26, 2025 /24-7PressRelease/ - Unite for HER (UFH) and Gilead Sciences have partnered to provide a new integrative care program free to Black, Hispanic, and underserved metastatic breast cancer patients in the United States.

BioPharma Dive
Jun 25th, 2025
Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

Gilead and Kymera will develop a molecular glue degrader for breast cancer and other solid tumors.

PR Newswire
Jun 1st, 2025
The Academy Of Oncology Nurse Patient Navigators And Gilead Sciences Partner To Launch Oncology Navigation Grant Program

GAINESVILLE, Fla., June 1, 2025 /PRNewswire/ -- The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the launch of a groundbreaking grant program in partnership with Gilead Sciences aimed at advancing the field of oncology navigation and enhancing patient outcomes within the healthcare setting. This initiative is designed to support the creation, enhancement, and expansion of innovative tools that optimize efficiency and elevate the critical role of oncology navigators.Following the AONN+ call for grant submissions in April, healthcare leaders across the country responded with creative applications, software solution ideas and healthcare system improvements. AONN+ looks to announce the recipients of the award, valued up to $500,000, in June with project work to begin in the July time frame. The AONN+ grant application process and implementation support for awardees also included help from Amplity, AONN+'s association management partner and strategic collaborator."Through this funding mechanism, AONN+ and Gilead are committed to addressing persistent challenges in cancer care by empowering navigators to play a pivotal role in improving patient access to navigation services, removing barriers to cancer care, and supporting treatment adherence," says Candice Roth, MSN, RN, CENP, Executive Director, AONN+. "Navigator utilization continues to present significant opportunities for optimizing patient outcomes, and this program seeks to provide impactful solutions that directly tie proposed tools to measurable improvements in patient care.""As part of Gilead's Community Cancer Collective, we are proud to partner with AONN+ on this exciting initiative in support of the oncology community," said Darren Tayama, M.D., Vice President, US Medical Affairs, Oncology. "Together, AONN+ and Gilead are advancing the future of cancer care through innovative solutions in oncology navigation."About the Academy of Oncology Nurse & Patient Navigators , Inc

Labiotech
May 27th, 2025
Interleukin Therapeutics: 9 Companies To Follow In 2025

Newsletter Signup - Under Article / In Page"*" indicates required fields Interleukins — a group of signaling proteins that help immune cells communicate — have long been recognized as powerful tools in modulating immune responses. Over the years, companies have explored interleukin as treatments for cancer, autoimmune conditions, and inflammatory diseases. But while some interleukin-based drugs have reached the market, many early attempts were held back by toxicity and a lack of precision.Today, that’s starting to change. Advances in protein engineering, mRNA technology, and cell-targeted delivery have opened up new ways to harness interleukins more safely and effectively. Big pharma is already active in this space, but a growing number of smaller biotech companies are helping to push the field forward.In this list, we take a look at some of the most interesting biotech companies and emerging players developing interleukin therapeutics. Ankyra Therapeutics Headquarters: Cambridge, MassachusettsFounded: 2019Recent News: Presented preliminary phase 1 clinical data for ANK-101 at the AACR Annual MeetingAnkyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of cytokine-based treatments. The company’s lead candidate, ANK-101 (tolododekin alfa), is an interleukin-12 (IL-12) cytokine anchored to aluminum hydroxide, designed for localized delivery to tumors.ANK-101 employs Ankyra’s proprietary Anchored Immunotherapy Platform, which involves fusing IL-12 with an alum-binding peptide, allowing the complex to bind to aluminum hydroxide (Alhydrogel)